Receptors, Fibroblast Growth Factor
"Receptors, Fibroblast Growth Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Specific molecular sites or structures on cell membranes that react with FIBROBLAST GROWTH FACTORS (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.
MeSH Number(s)
D12.776.543.750.750.400.370
Concept/Terms
Receptors, Fibroblast Growth Factor- Receptors, Fibroblast Growth Factor
- Receptors, FGF
- Fibroblast Growth Factor Receptor
- Fibroblast Growth Factor Receptors
- FGF Receptor
- Receptor, FGF
- FGF Receptors
Below are MeSH descriptors whose meaning is more general than "Receptors, Fibroblast Growth Factor".
Below are MeSH descriptors whose meaning is more specific than "Receptors, Fibroblast Growth Factor".
- Receptors, Fibroblast Growth Factor
- Receptor, Fibroblast Growth Factor, Type 1
- Receptor, Fibroblast Growth Factor, Type 2
- Receptor, Fibroblast Growth Factor, Type 3
- Receptor, Fibroblast Growth Factor, Type 4
- Receptor, Fibroblast Growth Factor, Type 5
This graph shows the total number of publications written about "Receptors, Fibroblast Growth Factor" by people in Harvard Catalyst Profiles by year, and whether "Receptors, Fibroblast Growth Factor" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 2 | 2 | 4 |
| 1995 | 4 | 2 | 6 |
| 1996 | 3 | 3 | 6 |
| 1997 | 2 | 0 | 2 |
| 1998 | 3 | 3 | 6 |
| 1999 | 3 | 2 | 5 |
| 2000 | 1 | 4 | 5 |
| 2001 | 2 | 3 | 5 |
| 2002 | 0 | 3 | 3 |
| 2003 | 2 | 6 | 8 |
| 2004 | 4 | 7 | 11 |
| 2005 | 1 | 1 | 2 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 2 | 1 | 3 |
| 2011 | 2 | 3 | 5 |
| 2012 | 2 | 1 | 3 |
| 2013 | 2 | 2 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 3 | 1 | 4 |
| 2016 | 1 | 4 | 5 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 4 | 4 | 8 |
| 2020 | 1 | 1 | 2 |
| 2021 | 5 | 1 | 6 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 2 | 2 |
Below are the most recent publications written about "Receptors, Fibroblast Growth Factor" by people in Profiles.
-
Dose-Dependent and Reversible Serous Retinal Detachments in Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2023 Jun; 54(6):368-370.
-
Targeting Epsins to Inhibit Fibroblast Growth Factor Signaling While Potentiating Transforming Growth Factor-ß Signaling Constrains Endothelial-to-Mesenchymal Transition in Atherosclerosis. Circulation. 2023 02 21; 147(8):669-685.
-
Autoantibodies Against Trisulfated Heparin Disaccharide and Fibroblast Growth Factor Receptor-3 May Play a Role in the Pathogenesis of Neuropathic Corneal Pain. Cornea. 2023 Jul 01; 42(7):821-828.
-
Fibroblast growth factor receptor inhibitor erdafitinib promotes Mcl-1 degradation and synergistically induces apoptosis with Bcl-xL/Bcl-2 inhibitor in urothelial cancer cells. Biochem Biophys Res Commun. 2022 11 05; 628:76-83.
-
RAB11A Expression Is Associated With Cancer Aggressiveness Through Regulation of FGFR-Signaling in Lung Squamous Cell Carcinoma. Ann Surg Oncol. 2022 Oct; 29(11):7149-7162.
-
FGFR-inhibitor-mediated dismissal of SWI/SNF complexes from YAP-dependent enhancers induces adaptive therapeutic resistance. Nat Cell Biol. 2021 11; 23(11):1187-1198.
-
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directions. Expert Rev Clin Pharmacol. 2021 Oct; 14(10):1233-1252.
-
Pilot Gene Expression and Histopathologic Analysis of Tracheal Resections in Tracheobronchomalacia. Ann Thorac Surg. 2022 11; 114(5):1925-1932.
-
Targeting fibroblast growth factor receptors to combat aggressive ependymoma. Acta Neuropathol. 2021 08; 142(2):339-360.
-
Halting the FGF/FGFR axis leads to antitumor activity in Waldenström macroglobulinemia by silencing MYD88. Blood. 2021 05 06; 137(18):2495-2508.